5:13 PM
 | 
May 06, 2013
 |  BC Extra  |  Clinical News

Celgene reports more apremilast data

Celgene Corp. (NASDAQ:CELG) reported additional data for apremilast on Monday and also announced revenue guidance for the oral phosphodiesterase-4 (PDE-4) inhibitor. In the Phase III PALACE-4 trial to treat psoriatic arthritis in patients who had not previously received a DMARD, twice-daily oral...

Read the full 198 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >